Recent Updates
Recently added Catalysts
MLTX Negative Sentiment

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

Key Takeaway: Bernstein Liebhard LLP has issued a reminder to investors of MoonLake Immunotherapeutics (NASDAQ: MLTX) regarding an impending deadline related to a securities fraud class action lawsuit. The lawsuit concerns allegations of misrepresentation about the company's drug candidate, sonelokimab, which was claimed to be superior to competing monoclonal antibodies. Investors who purchased shares between March 10, 2024, and September 29, 2025, are urged to take action if they wish to serve as lead plaintiffs in the case. The deadline for filing is December 15, 2025.
Price reaction · baseline $10.63 (2025-11-07 close) · 2 other MLTX headline(s) in the window, move may be shared
day 0 close · peak
+1.8%

Market Sentiment Analysis

CONCERNS & RISKS

  • A securities fraud class action lawsuit has been filed against MoonLake.
  • The lawsuit alleges misrepresentations concerning sonelokimab (SLK), the company's drug candidate.
  • Investors may have lost money related to their investment in MoonLake.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+83%
120-day peak, hindsight
Typical move
4.4%
average across 5 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
Sonelokimab
Phase 3 · Hidradenitis Suppurativa

Full Press Release Details

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
Do you, or did you, own shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)?
Did you purchase your shares between March 10, 2024 and September 29, 2025, inclusive?
Did you lose money in your investment in MoonLake Immunotherapeutics?
Do you want to discuss your rights?
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
If you purchased or acquired MoonLake common stock, and/or would like to discuss your legal rights and options please visit MoonLake Immunotherapeutics Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
A lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors (the “Class”) who purchased or acquired the common stock of MoonLake between March 10, 2024 and September 29, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.
According to the lawsuit, Defendants made misrepresentations concerning the Company’s sole drug candidate, sonelokimab (SLK), which was promoted as superior to competing monoclonal antibody drugs.
If you wish to serve as lead plaintiff for the Class, you must file papers by December 15, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Frequently Asked Questions

What is the deadline to file for the lead plaintiff role?

The deadline to file papers to serve as lead plaintiff is December 15, 2025.

What is the lawsuit against MoonLake about?

The lawsuit alleges securities fraud due to misrepresentations about MoonLake's drug candidate sonelokimab.

Who can participate in the class action lawsuit?

Anyone who purchased MoonLake shares between March 10, 2024, and September 29, 2025, can participate.

Are there any fees for shareholders in the lawsuit?

All representation is on a contingency fee basis; shareholders pay no fees or expenses.

How to contact Bernstein Liebhard LLP for more information?

You can contact Investor Relations Manager Peter Allocco at 212-951-2030 or via email.

Last updated: Nov 10, 2025